Industry landscapes
The companies, capital and talent shaping life sciences in London. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
39 of 717 tracked companies have open roles.
296 of 717 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 576 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 29.8% of disclosed capital, while 58.7% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $310.57M | 50 | 30 |
| 2017 | $781.21M | 55 | 45 |
| 2018 | $754M | 55 | 44 |
| 2019 | $433.28M | 63 | 49 |
| 2020 | $1.06B | 62 | 53 |
| 2021 | $1.35B | 45 | 67 |
| 2022 | $1.08B | 40 | 57 |
| 2023 | $847.66M | 33 | 49 |
| 2024 | $1.15B | 24 | 48 |
| 2025 | $1.49B | 11 | 36 |
Share of all disclosed company funding.
674 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by Thrive Capital and Alphabet and others.
Backed by 4Bio Capital and Servier and others.
Backed by Innovateuk.
Backed by Ananda Impact Ventures and Creator Fund.
Backed by .
Backed by Daphni and Pace Ventures and others.
Backed by .
Backed by FounderCatalyst.
Backed by Thrive Capital and Alphabet and others.
Backed by Thrive Capital and Google Ventures and others.
Backed by Forbion and General Atlantic and others.
Backed by Boehringer Ingelheim.
Backed by Future Fund and Ridgeback Capital Management and others.
Backed by Deerfield and Venrock and others.
Participating investors were not recorded in this snapshot.
Participating investors were not recorded in this snapshot.
Backed by RA Capital Management and Forbion and others.
Backed by TCG Crossover and BVF Partners and others.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · company accounts; aggregate reporting threshold not met · 2 reporting entities from 291 eligible matches.
Sum of reporting-entity revenue; not London market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
None of 2 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 2 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| SEERS Medical ↗06572698 | £0.0m | £0.6m | +33944.1% | — | — |
| Medical Genomics ↗04098979 | £0.0m | £-0.0m | -265.7% | — | — |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the London companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
6 of the 717 companies on this page carry a measured traffic record (0.8%); these are the largest of those, by monthly visits. The median among them is 402,232 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| Overleafoverleaf.com | 41,836,176 | 74 | 9.2% |
| Ankhwayankhway.com | 825,348 | 21 | 95.7% |
| Heightsheights.com | 593,889 | 38 | 92.7% |
| Second Naturesecondnature.io | 210,575 | 47 | 82.6% |
| Elvieelvie.com | 63,849 | 45 | 48.7% |
| Allplantsallplants.com | 12,536 | 34 | 83.2% |
Visits and authority are third-party web estimates, not company-reported figures.
31 of these companies (4.3%) publish at least one Android app — 46 apps in all, carrying 918.8K installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Pump with ElvieElvie | 239K | 4 | Health & Fitness |
| Second NatureSecond Nature | 225.9K | 3.9 | Health & Fitness |
| Caura: For #AllThingsCarCaura | 178.1K | — | Auto & Vehicles |
| Elvie TrainerElvie | 120K | 4.1 | Health & Fitness |
| ExSeed: Sperm & Fertility AppExseed Health | 54.2K | — | Health & Fitness |
| sofisofi | 25.9K | — | Health & Fitness |
| Little JourneyLittle Journey | 20.3K | — | Medical |
| bioniqBioniq | 8.8K | 2.8 | Health & Fitness |
| Atom5Aparito | 6.5K | 3.8 | Medical |
| HabitualHabitual | 6.3K | — | Health & Fitness |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2024Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Disease Self Management | 14 | 555.2K | Pump with Elvie 239K | |
| Wearable Technology | 12 | 547.8K | Caura: For #AllThingsCar 178.1K | |
| Women Health | 8 | 362.1K | Elvie Trainer 120K | |
| Online Mom & Baby Care | 5 | 361.6K | Neebo 2K | |
| Consumer Electronics E-Commerce | 4 | 359.6K | Elvie Strong | Kegel Exercises 644 | |
| Nutraceuticals Tech | 5 | 241.1K | Second Nature 225.9K | |
| Fitness & Wellness Tech | 12 | 237.8K | Habitual 6.3K | |
| Genitourinary Disorders | 2 | 54.3K | ExSeed: Sperm & Fertility App 54.2K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 36 of 46 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
28 companies hiring · $11.82B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Herbalife acquired the personalized nutrition company Bioniq
Digital Science’s acquisition of Ontopic aims to enhance research intelligence and knowledge discovery through advanced data integration and extraction technologies.
Avacta Group plc (...) has completed an oversubscribed equity raise of £10 million gross proceeds through a placing of 15,000,000 new ordinary shares and a director subscription for a further 873,016 shares
Compass Pathways announces exercise of $200 million in outstanding warrants.
Manchester-based private equity investor Palatine has pumped £5m into fast-growing, UK-based primary research platform Techspert with funding from its Growth Credit Fund to “drive headcount growth and further develop its AI offering.”
The Nue Co., which launched in Sephora in 2021, has raised roughly $36 million from investors such as Pamoja Capital, Unilever Ventures and REDO Ventures, the family office linked to the Geiger family, controlling shareholders of the L’Occitane Group.
The deal is expected to raise about $20 million in gross proceeds, with closing targeted for February 17, 2026, the announcement noted.
The raise includes a USD $10 million round led by Atomico, with participation from LocalGlobe, Mercuri and Samos Investments.
Automata lands $45M in Series C funding for AI-ready lab automation
Aptorum Group said on Monday that diagnostics firm DiamiR Biosciences and test developer Instant NanoBiosensors (INB) will collaborate to validate INB's automated apolipoprotein E (APOE) testing platform for Alzheimer's disease. Aptorum is in the process of merging with DiamiR.
Top 10 categories among 388 recorded events in the 24-month window.
7 companies with recorded IPO activity
Follow-on Offering · Nasdaq2 reports
Follow-on Offering · Nasdaq Capital Market2 reports
IPO · NASDAQ4 reports
IPO1 reports
IPO · Nasdaq1 reports
IPO1 reports
OFS1 reports
17 tracked people moves
Retirement Previously chief compliance officer
Appointment Chief Executive Officer
Appointment Board Member
Appointment Vice President and General Manager
Appointment Chief Executive Officer (Interim)
Departure Previously Chief Executive Officer
Appointment President and Chief Executive Officer
Retirement Previously Vice President and General Manager
2 recorded customer wins
Customer: Serono SA
Customer: astrazenecaBiotechnology
2 companies with reported reductions
65 rolestrading headwinds
30.0% rolescost reduction
10 recorded events
voucher grantedFDA
approved for tradingLondon Stock Exchange
anticipated FDA clearance by 2027FDA
2 tracked suits
Investor damages due to alleged misstatements of clinical trial outcomesClass Action · Ongoing
Misleading statements about Phase 3 studies leading to inflated share priceSecurities Fraud · Filed
Reported company results in the recorded window.
Median across 30 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| herbalife→Bioniq ↗ | Completed | 2026-04-14 | Not stated in snapshot |
| Digital Science→ontopic | Announced | 2026-03-30 | Not stated in snapshot |
| Merck & Co.→Verona Pharma ↗ | Announced | 2026-03-25 | $10.0B |
| shiseido→Gallinee Beaute ↗ | Completed | 2026-02-19 | Not stated in snapshot |
| Aptorum Group→DiamiR Biosciences | Pending | 2026-02-02 | Not stated in snapshot |
| Sinclair→The EW Scripps Company | Announced | 2026-01-19 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
1 postings in the preceding 12 months. The full 7-posting snapshot covers 4 employers.
0 tracked postings mention remote work.
Top skills across 7 tracked postings in the available jobs snapshot.
| Company | Employees |
|---|---|
| Judges Scientific ↗ | 622 |
| Digital Science ↗ | 116 |
| Silence Therapeutics ↗ | 105 |
| Second Nature ↗ | 91 |
| Avacta ↗ | 90 |
| LivaNova ↗ | 68 |
| Bioniq ↗ | 61 |
| Airfinity ↗ | 57 |
698 founders and chief executives across 452 companies.
University of Cambridge BA, UCL PhD
Kings College in London
Ex-Stirling Square Capital Partners, EMcision, Deutsche Bank. University of Bristol BSc 2007, Columbia Business School MBA 2013
Ex-Vyome Therapeutics, Aratana Therapeutics, Ikaria · Kalamazoo College BA 1988, The University of Chicago Booth School of Business MBA 1992
Ex-Co-Founder Aiolos Bio, Gyroscope Therapeutics. Wolverhampton University, Aston University MBA
Ex-Otsuka Pharmaceutical, Bristol-Myers Squibb, Smith & Nephew, Booz.Allen & Hamilton. University of Cambridge MA 1986, INSEAD MBA 1991
Autolus, ex-Kymab, ex-Kuros Biosciences, Stanford University School of Medicine, 1998
Quell Therapeutics, ex-Jazz Pharmaceuticals, ex-Eusa Pharma
CEO-Ori Biotech, Health Equity Consulting · Ex-Indivior, RB · University of Virginia BA 1997, Columbia Business School MBA 2003
Co-Founder Achilles Therapeutics. Pontifical Catholic University of Chile BS 1999
Elanco, ex-Phase4 Partners, ex-British Heart Foundation, The University of Birmingham, UK
Ex-CytoImmune Therapeutics, Rubius Therapeutics, Tmunity Therapeutics · Temple University BS 1992, University of Pennsylvania PhD 1999
203 profiles with education records.
14 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
30,139 articles in the measured 12-month window.
Life Sciences coverage tagged London · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 6,032 |
| 2021Q3 | 5,447 |
| 2021Q4 | 5,522 |
| 2022Q1 | 5,762 |
| 2022Q2 | 5,964 |
| 2022Q3 | 7,064 |
| 2022Q4 | 6,208 |
| 2023Q1 | 5,779 |
| 2023Q2 | 6,686 |
| 2023Q3 | 5,372 |
| 2023Q4 | 6,066 |
| 2024Q1 | 7,205 |
| 2024Q2 | 6,976 |
| 2024Q3 | 6,497 |
| 2024Q4 | 6,402 |
| 2025Q1 | 15,178 |
| 2025Q2 | 6,699 |
| 2025Q3 | 8,099 |
| 2025Q4 | 6,542 |
| 2026Q1 | 8,479 |
Article volume measures coverage, not market sales.
548 recorded company events across 74 companies; percentages use that event total.
Life Sciences coverage tagged London · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
United Kingdom comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| tariff negotiations | 1,105 | 472 | 134% |
| angel investors | 1,088 | 428 | 154% |
| free trade deals | 628 | 238 | 164% |
| vaccine candidates | 603 | 394 | 53% |
| bilateral trade | 555 | 135 | 311% |
| vaccine immunogenicity | 472 | 266 | 77% |
| vaccination campaigns | 454 | 153 | 197% |
| trade dispute mechanisms | 452 | 164 | 176% |
| asset acquisition | 449 | 148 | 203% |
| early-stage investment | 445 | 143 | 211% |
| investigational new vaccine | 134 | 506 | -74% |
| vaccine formulation | 178 | 463 | -62% |
| viral vector vaccines | 147 | 453 | -68% |
| vaccine preclinical testing | 97 | 373 | -74% |
| diagnostic biotechnology | 186 | 369 | -50% |
United Kingdom comparison coverage
inflation outlook, core inflation rate, inflation breakdown
54.0% critical · 32.2% positiveangel investors, early-stage investment, asset acquisition
45.5% critical · 50.6% positivegdp acceleration, gdp growth rate, inflation outlook
38.3% critical · 42.9% positiveLife Sciences coverage tagged London. Topic labels describe recorded classifications and can include broad context.
53,147 papers in the recorded worldwide scope.
Tone counts: 42,568 positive · 8,415 neutral · 2,164 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
Common problems researchers identify · 0117.3% of this theme group
Researchers discuss challenges in using microbes and plants for renewable fuels and biorefinery processes.
Biofuel (41) · Synthetic biology (53) · Biomass (45) · Biorefinery (28)
A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application
Biofertilizers: An ecofriendly technology for nutrient recycling and environmental sustainability
| Year | Share index |
|---|---|
| 2022 | 60.6 |
| 2023 | 59.3 |
| 2024 | 61.9 |
| 2025 | 67.0 |
Common problems researchers identify · 0216.8% of this theme group
Papers highlight microbial hazards and nutritional impacts linked to food manufacturing and consumer health.
Food safety (130) · Food processing (74) · Food products (50) · Human health (90)
Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures
Nutritional quality and processing of plant proteins for healthy and sustainable foods
| Year | Share index |
|---|---|
| 2022 | 70.2 |
| 2023 | 72.4 |
| 2024 | 77.4 |
| 2025 | 99.2 |
Common problems researchers identify · 0315.8% of this theme group
Studies examine hurdles in controlling gene activity, mRNA delivery, and cell‑culture models for disease treatment.
Messenger RNA (28) · Gene (44) · Cell culture (23) · Gene expression (24)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with
| Year | Share index |
|---|---|
| 2022 | 2510.1 |
| 2023 | 2495.8 |
| 2024 | 2199.0 |
| 2025 | 1697.8 |
Common problems researchers identify · 0415.4% of this theme group
Research points to difficulties in improving plant nutrient uptake and breeding crops for resilient food supplies.
Agriculture (208) · Crop (84) · Food security (86) · Germplasm (39)
Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants
Breeding for nutrient use efficiency in crop plants: Mechanistic insights, genetic determinants, and emerging breeding technologies
| Year | Share index |
|---|---|
| 2022 | 1635.2 |
| 2023 | 1667.4 |
| 2024 | 1799.9 |
| 2025 | 2026.9 |
Common problems researchers identify · 0515.3% of this theme group
Works address obstacles in pest control, host resistance, and integrated management of plant pathogens.
Fungicide (44) · Integrated pest management (54) · Host (41) · Disease management (32)
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
Insect-Borne Plant Pathogens and Their Vectors: Ecology, Evolution, and Complex Interactions
| Year | Share index |
|---|---|
| 2022 | 27.8 |
| 2023 | 29.2 |
| 2024 | 27.8 |
| 2025 | 37.2 |
Common problems researchers identify · 069.9% of this theme group
Literature flags the spread of drug‑resistant microbes in humans, livestock, and the environment.
Antibiotic resistance (301) · Antimicrobial (164) · Antibiotics (126) · Drug resistance (49)
Antimicrobial resistance in humans, livestock and the wider environment
Antimicrobial use and resistance
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.4% of this theme group
Papers cover a range of unrelated scientific themes, from molecular order to interdisciplinary analyses.
Order (19) · NAD+ kinase (11) · Human being (12) · Sodium (11)
Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar
Obiteljska grupna konferencija: prilika za građansko pravosuđe?
| Year | Share index |
|---|---|
| 2022 | 18.4 |
| 2023 | 21.9 |
| 2024 | 17.8 |
| 2025 | 12.5 |
Cautions · 0121.5% of this theme group
Authors urge caution interpreting in‑vitro and in‑vivo assays due to stress‑related artifacts.
In vivo (32) · Flow cytometry (16) · In vitro (27) · Oxidative stress (19)
Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells
Cell Painting for cytotoxicity and mode-of-action analysis in primary human hepatocytes
| Year | Share index |
|---|---|
| 2022 | 1034.9 |
| 2023 | 1110.3 |
| 2024 | 911.7 |
| 2025 | 818.5 |
Cautions · 0214.6% of this theme group
Studies caution about translating genomic predictions into practical crop improvement outcomes.
Agriculture (45) · Selection (26) · Production (28) · Trait (16)
Genomic selection in plant breeding: from theory to practice
Future Directions for Sustainable Poultry Feeding and Product Quality: Alternatives from Insects, Algae and Agro-Industrial Fermented By-Pro
| Year | Share index |
|---|---|
| 2022 | 1437.3 |
| 2023 | 1478.4 |
| 2024 | 1637.4 |
| 2025 | 1817.4 |
Cautions · 0313.9% of this theme group
Research warns of unintended effects when introducing novel bioactive compounds into livestock diets.
Feed additive (27) · Animal feed (28) · Feed conversion ratio (32) · Health benefits (30)
Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production
The impact of substituting animal with plant protein foods in adults’ self-selected diets on environmental, nutritional, and health outcomes
| Year | Share index |
|---|---|
| 2022 | 22.2 |
| 2023 | 20.9 |
| 2024 | 17.3 |
| 2025 | 18.2 |
Cautions · 0413.6% of this theme group
Papers highlight uncertainties around safety assessments for emerging food additives and contaminants.
Food safety (66) · Hygiene (21) · Contamination (29) · Food contaminant (20)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Insect-derived food colorants: Chemistry, applications, safety, and regulatory perspectives
| Year | Share index |
|---|---|
| 2022 | 91.3 |
| 2023 | 89.1 |
| 2024 | 95.4 |
| 2025 | 105.8 |
Cautions · 0513.5% of this theme group
Works stress the complexity of interpreting gene‑expression changes linked to genomic instability.
Gene (41) · DNA damage (26) · DNA repair (13) · Gene expression (20)
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
| Year | Share index |
|---|---|
| 2022 | 2415.6 |
| 2023 | 2417.4 |
| 2024 | 2125.5 |
| 2025 | 1613.8 |
Cautions · 0611.7% of this theme group
Authors caution that antimicrobial practices can foster resistance to multiple chemical agents.
Antibiotic resistance (59) · Antibiotics (47) · Antimicrobial (38) · Bacteria (26)
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses
Co-Selection of Resistance to Antibiotics, Biocides and Heavy Metals, and Its Relevance to Foodborne Pathogens
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Cautions · 0711.3% of this theme group
Research advises careful dosing strategies to avoid accelerating resistance in pest populations.
Pesticide (34) · Integrated pest management (21) · PEST analysis (30) · Biological pest control (20)
The use of fungal entomopathogens as endophytes in biological control: a review
Managing pesticide resistance by changing the applied dose: a modeling analysis incorporating pesticide persistence and including low-dose m
| Year | Share index |
|---|---|
| 2022 | 66.9 |
| 2023 | 65.3 |
| 2024 | 66.9 |
| 2025 | 75.8 |
Opportunities · 0117.4% of this theme group
Opportunities arise from novel antibody formats and fluorescence methods for in‑vivo cell analysis.
Antibody (70) · In vivo (81) · Fluorescence (40) · Flow cytometry (50)
Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom
Preparation, Characterization, and Binding Mechanism of Nanobodies Targeting Multiple Serotypes of <i>Salmonella</i>
| Year | Share index |
|---|---|
| 2022 | 561.4 |
| 2023 | 615.1 |
| 2024 | 467.1 |
| 2025 | 455.3 |
Opportunities · 0217.2% of this theme group
Studies explore targeted gene knockdown and regulation to influence apoptosis and cell growth.
Downregulation and upregulation (106) · Apoptosis (80) · Gene knockdown (103) · Cell growth (43)
Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc
RasGRP3 Promotes RAP1B Activity to Inhibit Endothelial Inflammation and Alleviate Atherosclerosis in High-Fat Diet-Fed ApoE−/− Mice
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0314.6% of this theme group
Research points to health‑promoting ingredients and antioxidants in sustainable, plant‑derived food products.
Health benefits (78) · Functional food (61) · Ingredient (48) · Antioxidant (69)
Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives
PLANT-BASED PROTEINS: SOURCES, EXTRACTION METHODS AND FUNCTIONAL PERSPECTIVES FOR THE SUSTAINABLE FOOD INDUSTRY
| Year | Share index |
|---|---|
| 2022 | 26.7 |
| 2023 | 26.2 |
| 2024 | 27.1 |
| 2025 | 45.2 |
Opportunities · 0413.7% of this theme group
Papers reveal potential of DNA methylation and messenger‑RNA markers for detecting disease states.
Gene (164) · DNA methylation (60) · Messenger RNA (76) · DNA damage (55)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
Stimuli-ResponsiveFusion of Binary-Star IntelligentDNA System for the Signal-On Amplification Detection of Cancer-RelatedmiRNA
| Year | Share index |
|---|---|
| 2022 | 2397.7 |
| 2023 | 2377.6 |
| 2024 | 2114.7 |
| 2025 | 1613.7 |
Opportunities · 0513.5% of this theme group
Opportunities include discovering plant‑derived antimicrobials and microbial metabolites to boost animal health.
Antimicrobial (126) · Antibiotic resistance (66) · Biological pest control (54) · Bacteria (87)
Plants as sources of new antimicrobials and resistance-modifying agents
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 524.8 |
| 2023 | 510.4 |
| 2024 | 554.5 |
| 2025 | 649.8 |
Opportunities · 0611.9% of this theme group
Research focuses on leveraging germplasm and quantitative trait loci to enhance yield and quality.
Germplasm (71) · Trait (52) · Quantitative trait locus (40) · Selection (53)
Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield
GENETIC VARIABILITY ANALYSIS FOR YIELD AND RELATED TRAITS IN WHEAT (TRITICUM AESTIVUM L.) MUTANT GENOTYPES
| Year | Share index |
|---|---|
| 2022 | 53.0 |
| 2023 | 45.3 |
| 2024 | 39.2 |
| 2025 | 40.8 |
Opportunities · 0711.6% of this theme group
Studies highlight microbial fermentation and by‑product valorization for greener agriculture and energy.
Biomass (67) · Sustainability (77) · Agriculture (102) · Biofuel (35)
Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health
Bioactive Compounds From Agri‐Food By‐Products: Advancements in Environmental Sustainability and Bioeconomic Progress
| Year | Share index |
|---|---|
| 2022 | 1514.8 |
| 2023 | 1566.1 |
| 2024 | 1742.6 |
| 2025 | 1980.2 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Descriptive | 40.2% | 17.4% |
| Promising | 30.4% | 37.4% |
| Breakthrough | 14.1% | 26.1% |
| Problem-identifying | 8.3% | 9.8% |
| Cautionary | 3.5% | 4.3% |
| Comparative | 2.4% | 4.1% |
| Critical | 1.0% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 87 | 0.21% | 25 (28.7%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 61 | 0.15% | 4 (6.6%) | 0.15% |
| Bias & fairnessGeographic Prevalence Heterogeneity Creates Unavoidable Fairness-Accuracy Trade-offs in Antimicrobial Resistance Predict | 12 | 0.03% | 2 (16.7%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 3 | 0.01% | 3 (100.0%) | 0.01% |
| Energy & datacenter footprintIntegration of GWAS and WGCNA Identifies PUE‐Related Gene <i>TaERF112</i> in Wheat | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Compare demand signals in London’s newsflow with the life sciences categories mapped to each signal.
Signal percentile − supply percentile = gap in percentile points. Positive gaps highlight questions to investigate. A high signal can reflect spending pressure or access friction, as well as potential demand.
The comparison is relative to the signal families on this page. A supply percentile of zero means the lowest relative reading, not zero companies. It is a prioritisation clue, not measured market size or unmet demand.
Signal and mapped-supply percentiles, their gap, and change in the signal’s article share.
Swipe horizontally to compare all columns →
| Signal family | Signal percentile | Supply percentile | Relative gap | Gap (points) | Signal share vs prior year |
|---|---|---|---|---|---|
| Layoffs & income shocks ↗Spending Pressure | 87.5 | 33.3 | +54.2 | +10.1% | |
| Maternal & child health ↗Disease Burden | 33.3 | 0.0 | +33.3 | +5.6% | |
| Cancer burden ↗Disease Burden | 41.7 | 66.7 | -25.0 | -27.1% | |
| Diabetes, hypertension & cardiac burden ↗Disease Burden | 25.0 | 100.0 | -75.0 | — | |
| Air pollution ↗Environmental Driver | 45.8 | — | No matching category | — | -1.2% |
| Mental health ↗Disease Burden | 50.0 | — | No matching category | — | — |
| Ageing & elder care ↗Disease Burden | 66.7 | — | No matching category | — | +17.4% |
Showing all 7 signals. Select a family for its history and mapped categories.
All 12 city readings for these demand families in the comparison geography. London is highlighted.
Each city’s reading is a share of its own coverage. Rows cover all of the United Kingdom for this page's signal families; London is marked.
Cancer burden · Diabetes, hypertension & cardiac burden · Layoffs & income shocks
Ageing & elder care · Mental health · Maternal & child health
Maternal & child health · Mental health · Layoffs & income shocks
Mental health · Cancer burden · Layoffs & income shocks
Maternal & child health · Cancer burden · Ageing & elder care
Mental health · Maternal & child health · Air pollution
Layoffs & income shocks · Cancer burden · Mental health
Cancer burden · Mental health · Layoffs & income shocks
Layoffs & income shocks · Cancer burden · Air pollution
Maternal & child health · Layoffs & income shocks · Cancer burden
Cancer burden · Layoffs & income shocks · Maternal & child health
Maternal & child health · Layoffs & income shocks · Cancer burden
Layoff cycles can pull discretionary spend back toward value offerings.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 54 | 21.03 |
| 2024Q4 | 61 | 26.01 |
| 2025Q1 | 84 | 31.68 |
| 2025Q2 | 50 | 20.77 |
| 2025Q3 | 84 | 27.61 |
| 2025Q4 | 43 | 17.83 |
| 2026Q1 | 109 | 35.03 |
Maternal and child burden can pull immunisation, nutrition and pediatric care demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 22 | 8.57 |
| 2024Q4 | 14 | 5.97 |
| 2025Q1 | 19 | 7.16 |
| 2025Q2 | 7 | 2.91 |
| 2025Q3 | 28 | 9.2 |
| 2025Q4 | 12 | 4.98 |
| 2026Q1 | 28 | 9.0 |
Cancer burden can pull screening, diagnostics and oncology capacity demand.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 34 | 13.24 |
| 2024Q4 | 33 | 14.07 |
| 2025Q1 | 83 | 31.3 |
| 2025Q2 | 60 | 24.93 |
| 2025Q3 | 26 | 8.55 |
| 2025Q4 | 53 | 21.98 |
| 2026Q1 | 42 | 13.5 |
Chronic cardiometabolic burden can turn into decades of management demand per patient.
Companies can appear in multiple categories; these counts are not a unique-company total.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 20 | 7.79 |
| 2024Q4 | 6 | 2.56 |
| 2025Q1 | 9 | 3.39 |
| 2025Q2 | 15 | 6.23 |
| 2025Q3 | 17 | 5.59 |
| 2025Q4 | 17 | 7.05 |
| 2026Q1 | 12 | 3.86 |
Sustained air-quality stress can pull respiratory and cardiac care demand with it.
This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 15 | 5.84 |
| 2024Q4 | 24 | 10.23 |
| 2025Q1 | 32 | 12.07 |
| 2025Q2 | 29 | 12.05 |
| 2025Q3 | 54 | 17.75 |
| 2025Q4 | 20 | 8.29 |
| 2026Q1 | 17 | 5.46 |
Mental-health pressure can pull counselling and tele-psychiatry demand where it surfaces.
This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 7 | 2.73 |
| 2024Q4 | 12 | 5.12 |
| 2025Q1 | 9 | 3.39 |
| 2025Q2 | 9 | 3.74 |
| 2025Q3 | 46 | 15.12 |
| 2025Q4 | 9 | 3.73 |
| 2026Q1 | 34 | 10.93 |
An ageing base can shift demand toward geriatric, home and chronic care.
This signal has no matching category in the page’s life sciences market map, so no supply percentile or gap is assigned.
Mentions per 10,000 articles · zero baseline
| Quarter | Mentions | Per 10,000 articles |
|---|---|---|
| 2024Q3 | 14 | 5.45 |
| 2024Q4 | 16 | 6.82 |
| 2025Q1 | 19 | 7.16 |
| 2025Q2 | 11 | 4.57 |
| 2025Q3 | 42 | 13.81 |
| 2025Q4 | 9 | 3.73 |
| 2026Q1 | 12 | 3.86 |
London life sciences coverage
BMJ
610 citations in the snapshot
The Lancet Infectious Diseases
455 citations in the snapshot
Clinical Infectious Diseases
252 citations in the snapshot
Clinical Infectious Diseases
241 citations in the snapshot
London coverage of this page's demand families
| Keyword | Recent articles | Prior articles | Share change |
|---|---|---|---|
| daycare vaccination rules | 40 | 8 | 345.9% |
| vaccine requirements for minors | 37 | 8 | 312.5% |
| childhood immunization laws | 40 | 10 | 256.7% |
| pediatric catch-up vaccinations | 40 | 11 | 224.3% |
| pollution monitoring | 22 | 15 | 30.8% |
| air quality standards | 26 | 19 | 22.0% |
Share changes describe coverage in the stated comparison periods, not search demand or market size.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 1 September 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗